Literature DB >> 25066214

Effect of dosimetric factors on occurrence and volume of temporal lobe necrosis following intensity modulated radiation therapy for nasopharyngeal carcinoma: a case-control study.

Xin Zhou1, Xiaomin Ou1, Tingting Xu1, Xiaosheng Wang1, Chunying Shen1, Jianhui Ding2, Chaosu Hu3.   

Abstract

PURPOSE: To determine dosimetric risk factors for the occurrence of temporal lobe necrosis (TLN) among nasopharyngeal carcinoma (NPC) patients treated with intensity modulated radiation therapy (IMRT) and to investigate the impact of dose-volume histogram (DVH) parameters on the volume of TLN lesions (V-N). METHODS AND MATERIALS: Forty-three NPC patients who had developed TLN following IMRT and 43 control subjects free of TLN were retrospectively assessed. DVH parameters included maximum dose (Dmax), minimum dose (Dmin), mean dose (Dmean), absolute volumes receiving specific dose (Vds) from 20 to 76 Gy (V20-V76), and doses covering certain volumes (Dvs) from 0.25 to 6.0 cm(3) (D0.25-D6.0). V-Ns were quantified with axial magnetic resonance images.
RESULTS: DVH parameters were ubiquitously higher in temporal lobes with necrosis than in healthy temporal lobes. Increased Vds and Dvs were significantly associated with higher risk of TLN occurrence (P<.05). In particular, Vds at a dose of ≥70 Gy were found with the highest odds ratios. A common increasing trend was detected between V-N and DVH parameters through trend tests (P for trend of <.05). Linear regression analysis showed that V45 had the strongest predictive power for V-N (adjusted R(2) = 0.305, P<.0001). V45 of <15.1 cm(3) was relatively safe as the dose constraint for preventing large TLN lesions with V-N of >5 cm(3).
CONCLUSIONS: Dosimetric parameters are significantly associated with TLN occurrence and the extent of temporal lobe injury. To better manage TLN, it would be important to avoid both focal high dose and moderate dose delivered to a large area in TLs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25066214     DOI: 10.1016/j.ijrobp.2014.05.036

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Intensity-modulated radiotherapy and volumetric-modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment.

Authors:  Jun Zhang; Xiao-Ling Yu; Guo-Feng Zheng; Fei Zhao
Journal:  Med Oncol       Date:  2015-03-01       Impact factor: 3.064

2.  Radiation-induced brain structural and functional abnormalities in presymptomatic phase and outcome prediction.

Authors:  Zhongxiang Ding; Han Zhang; Xiao-Fei Lv; Fei Xie; Lizhi Liu; Shijun Qiu; Li Li; Dinggang Shen
Journal:  Hum Brain Mapp       Date:  2017-10-23       Impact factor: 5.038

3.  Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma.

Authors:  Christopher R Peeler; Dragan Mirkovic; Uwe Titt; Pierre Blanchard; Jillian R Gunther; Anita Mahajan; Radhe Mohan; David R Grosshans
Journal:  Radiother Oncol       Date:  2016-11-16       Impact factor: 6.280

4.  Review of photon and proton radiotherapy for skull base tumours.

Authors:  Piero Fossati; Andrea Vavassori; Letizia Deantonio; Eleonora Ferrara; Marco Krengli; Roberto Orecchia
Journal:  Rep Pract Oncol Radiother       Date:  2016-04-16

5.  Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma.

Authors:  Emma Holliday; Onita Bhattasali; Merrill S Kies; Ehab Hanna; Adam S Garden; David I Rosenthal; William H Morrison; G Brandon Gunn; Jack Phan; X Ronald Zhu; Xiaodong Zhang; Steven J Frank
Journal:  Int J Part Ther       Date:  2016-03-24

6.  Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.

Authors:  Xiaomin Ou; Xin Zhou; Qi Shi; Xing Xing; Youqi Yang; Tingting Xu; Chunying Shen; Xiaoshen Wang; Xiayun He; Lin Kong; Hongmei Ying; Chaosu Hu
Journal:  Oncotarget       Date:  2015-11-10

7.  Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma.

Authors:  Fen Xue; Chaosu Hu; Xiayun He
Journal:  Onco Targets Ther       Date:  2017-07-06       Impact factor: 4.147

8.  Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy.

Authors:  Fen Xue; Chao-Su Hu; Xia-Yun He
Journal:  Chin J Cancer       Date:  2017-09-20

9.  Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base.

Authors:  Sarin Kitpanit; Anna Lee; Ken L Pitter; Dan Fan; James C H Chow; Brian Neal; Zhiqiang Han; Pamela Fox; Kevin Sine; Dennis Mah; Lara A Dunn; Eric J Sherman; Loren Michel; Ian Ganly; Richard J Wong; Jay O Boyle; Marc A Cohen; Bhuvanesh Singh; Cameron W Brennan; Igor T Gavrilovic; Vaios Hatzoglou; Bernard O'Malley; Kaveh Zakeri; Yao Yu; Linda Chen; Daphna Y Gelblum; Jung Julie Kang; Sean M McBride; Chiaojung J Tsai; Nadeem Riaz; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2020-05-28

10.  LASSO-based NTCP model for radiation-induced temporal lobe injury developing after intensity-modulated radiotherapy of nasopharyngeal carcinoma.

Authors:  Cheng Kong; Xiang-Zhi Zhu; Tsair-Fwu Lee; Ping-Bo Feng; Jian-Hua Xu; Pu-Dong Qian; Lan-Fang Zhang; Xia He; Sheng-Fu Huang; Yi-Qin Zhang
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.